StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

Earnings

Akebia Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$36.90M
-37.2% on a year earlier
EPS, Q3 FY2026
-$0.05
$0.00 a year earlier
Latest guidance
Issued
Jan 12, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Akebia Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$36.90M-37.2%-$0.05Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$49.10M-21.4%-$0.03Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$53.50M-6.6%-$0.03Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$57.60M+23.9%-$0.05Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open$58.80M+57.2%$0.00Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$62.50M+43.3%–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$57.30M+75.8%–Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025before the open$46.50M-17.3%–Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$37.40M-11.0%-$0.10Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$43.60M-22.7%-$0.04Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$32.60M-18.7%-$0.09Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Akebia Therapeutics guided for has been reported

Guidance vs results

The last range Akebia Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q4 FY2025Revenue$5.00M – $6.00M$57.60MAbove range
Q1 FY2025Revenue$10.00M – $11.00M$57.30MAbove range

Guidance history

Every forecast Akebia Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jan 12, 2026Vafseo net product revenueQ4 FY2025$5.00M – $6.00MNew
Mar 13, 2025Vafseo net product revenuesQ1 FY2025$10.00M – $11.00MNew
Nov 8, 2023net product revenueFY2023$170.00M – $175.00MLowered
Aug 25, 2023Auryxia net product revenueFY2023$175.00M – $180.00MReaffirmed
May 8, 2023Auryxia net product revenueFY2023$175.00M – $180.00MReaffirmed
Mar 9, 2023Auryxia revenue guidanceFY2023$175.00M – $180.00MNew
Nov 3, 2022Auryxia net product revenueFY2022$170.00M – $175.00MReaffirmed
Aug 4, 2022net product revenueFY2022$170.00M – $175.00MRaised
May 9, 2022net product revenueFY2022$165.00M – $170.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Akebia Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Results
  4. Update
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?